Cargando…

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

OBJECTIVE: Analyze tofacitinib efficacy and safety by background methotrexate (MTX) dose in patients with psoriatic arthritis (PsA). METHODS: This post hoc analysis pooled data from two phase III, double-blind trials (OPAL Broaden, NCT01877668; OPAL Beyond, NCT01882439) including patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kivitz, Alan J., FitzGerald, Oliver, Nash, Peter, Pang, Shirley, Azevedo, Valderilio F., Wang, Cunshan, Takiya, Liza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782818/ https://www.ncbi.nlm.nih.gov/pubmed/34510295 http://dx.doi.org/10.1007/s10067-021-05894-2

Ejemplares similares

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
por: Burmester, Gerd R., et al.
Publicado: (2020)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
por: Fleischmann, R, et al.
Publicado: (2016)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
por: Nash, Peter, et al.
Publicado: (2020)

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
por: Ritchlin, Christopher T., et al.
Publicado: (2020)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
por: Nash, Peter, et al.
Publicado: (2018)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
por: de Vlam, Kurt, et al.
Publicado: (2022)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
por: Mease, Philip J., et al.
Publicado: (2023)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
por: Ciurea, Adrian, et al.
Publicado: (2023)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
por: Coates, Laura C., et al.
Publicado: (2021)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Risk factors and predictors of psoriatic arthritis in patients with psoriasis
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2013)

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
por: Strand, Vibeke, et al.
Publicado: (2018)

Psoriatic arthritis: from pathogenesis to therapy
por: FitzGerald, Oliver, et al.
Publicado: (2009)

Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis
por: Pennington, Stephen R., et al.
Publicado: (2021)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Cardiovascular Comorbidities in Psoriatic Disease
por: Szentpetery, Agnes, et al.
Publicado: (2019)

Psoriatic arthritis synovial histopathology: commentary on the article by Kruithof and colleagues
por: FitzGerald, Oliver
Publicado: (2005)

The many faces of psoriatic arthritis: their genetic determinism
por: Winchester, Robert, et al.
Publicado: (2020)

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
por: Mease, Philip, et al.
Publicado: (2022)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly, Karen, et al.
Publicado: (2019)

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies
por: Gladman, Dafna D., et al.
Publicado: (2019)

Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype
por: FitzGerald, Oliver, et al.
Publicado: (2015)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Early biomarkers of joint damage in rheumatoid and psoriatic arthritis
por: Mc Ardle, Angela, et al.
Publicado: (2015)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
por: Leng, Xiaomei, et al.
Publicado: (2023)

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
por: Karpouzas, George A., et al.
Publicado: (2023)

Methotrexate/tofacitinib/tozinameran interaction: COVID-19 pneumonia: case report
Publicado: (2022)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7l9plrhnupeeubjg1h2ognstoq